Stockbabie NewsFatherMarketNewsMarket Intelligence
MARKETS
Wire · Markets
Markets

Eos SENOLYTIX Presents New Preclinical Survival, Healthspan, Mechanism-Of-Action Data For Its PTC-2105 Candidate At 17th World Congress On Targeting Mitochondria 2026

Oct 22, 2026 · 08:09 AM ET· updated 3h ago

Eos SENOLYTIX, Inc. ("Eos" or the "Company") a biotechnology company developing mitochondria-targeted geropeptides to improve healthspan, today presented new preclinical survival, healthspan and

Share
Why It Matters

Eos showed lab results for a drug that might help people live better longer. Watch if they move toward human testing to know if it really works.

This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.
Tickers in Play
PULM1.62
+0.19 (+13.29%)

Last session drawn · prints held ~15 minutes · licensed exchange data

Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.

Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.